Who we are?

We are committed to discovering, developing and commercializing best-in-class and/or first-in-class drugs for the treatment of cancer and autoimmune diseases. Led by a world-class management team of seasoned industry executives, we have built a fully integrated biopharmaceutical platform with strong in-house R&D capabilities, including drug target identification and verification, preclinical evaluation, clinical trial design and execution, drug manufacturing and quality control, and commercialization.

Our Pipeline

We focus on the discovery and development of innovative medicines to address significant unmet medical needs of diseases that are specially prevalence in Chinese population.

Dedicated and Deliver

We have built a fully integrated biopharmaceutical platform that allows us to oversee all aspects of the drug development cycle. By having all functions in-house, we are able to improve operational efficiency and control quality every step of the way.

Company News
22/11/2022

InnoCare Announces Approval of HIBRUKA (Orelabrutinib) for the Treatment of Mantle Cell Lymphoma in Singapore

14/11/2022

InnoCare Releases 2022 Third Quarter Results: Star Board Listing for Long-term Growth and Rapid Increase of Orelabrutinib Sales

08/11/2022

10 Studies on Orelabrutinib Selected at the Upcoming 64th Annual Meeting of ASH